Tom Dacey’s Post

🔬 Breakthrough in Cancer Treatment: CAR T-Cell Therapy Unveiled 🧬 Excited to share our article on the revolutionary world of Cellular and Gene Therapy Products (CGTs), with a spotlight on CAR T-cell therapy for hematological malignancies. Key highlights: ✅Evolution and advantages of CAR T-cell therapy ✅Advantages over conventional therapies ✅Challenges in manufacturing and regulation ✅Safety concerns and risk mitigation strategies Discover how this ingenious biopharmaceutical class offers hope where conventional treatments fall short. Whether you're in healthcare, biotech, or simply curious about cutting-edge medical advancements, this article provides valuable insights into the future of cancer treatment. Ready to dive deeper? Find the link to the full article in the comments below. #CancerResearch #GeneTherapy #Biotechnology #MedicalInnovation #Healthcare #APCER #CARTCellTherapy #CGT #ATMP

Have you saved your spot at 🚀 Propel Launch Summit 🚀 yet? If you haven’t registered for this one-of-a-kind experience focused on launching products in oncology, rare disease, and cell and gene therapy, today’s the day! Propel Launch Summit takes off May 20-22, 2024 in Indianapolis. As a CEO, CCO, or other leader of commercialization or market access teams involved in launches, you’ll have the chance to: -Identify launch blind spots -Have 1:1 time with industry leaders and peers -Get insight into market dynamics, payer intelligence, and trends -Walk away with a game plan for launch success Register to get fueled up for your launch now! propellaunch.com #propellaunch #propellaunchsummit #biopharma #marketaccess #patientaccess #druglaunch #oncology #raredisease #cellandgenetherapy #celltherapy #genetherapy #complexconditions #rarediseases #launchsuccess #pharmalaunch #biopharmalaunch

🚀 BIG ANNOUNCEMENT! 🚀 Registration opens TODAY for Propel Launch Summit, an immersive learning experience focused on launching products in oncology, rare disease, and cell and gene therapy. Propel Launch Summit will take place May 20-22, 2024 in Indianapolis. As a CEO, CCO, or other leader of commercialization or market access teams involved in launches, you won’t want to miss your chance to: -Identify your launch blind spots -Have 1:1 time with industry leaders and peers -Get insight into market dynamics, payer intelligence, and trends -Walk away with a game plan for launch success As leaders in biopharma market access for nearly 25 years, we at DKP know how mission critical it is to get your launch right the first time. That’s why we’re thrilled to bring you this power-packed, curated experience focused on ensuring robust launches. Tickets are limited so register today! PropelLaunch.com #propellaunch #propellaunchsummit #biopharma #marketaccess #patientaccess #druglaunch #oncology #raredisease #cellandgenetherapy #celltherapy #genetherapy #complexconditions #rarediseases #launchsuccess #pharmalaunch #biopharmalaunch

Great to see the released webinar hosted by lead life science publication Drug Discovery World, and hosted by Reece Armstrong. The webinar is called "What are the challenges and advancements driving CGT drug development?” and has contributions from Ali Pashazadeh, CEO, Treehill Partners, and Erik Digman Wiklund, CEO, Circio Holding ASA . It's available below on demand. Ali explored current barriers and perceptions to the development of #CGTs, examining aspects such as #investment and attitudes towards #scalingup #therapies to treat #diseases such as #cancer. Erik Wiklund discussed how circular RNA #circRNA is crucial to the development of #nextgeneration #celltherapy and #genetherapy products. https://lnkd.in/emTU3QcN

Big confluence of factors driving an ever bigger market opportunity. The War on Cancer will never end, and never not keep attracting outsized investment up and down the stack. "The market is primarily driven by factors such as an increase in technological advancements, a rise in cancer incidences, and improvements in personalized medicine and cell and gene therapies, which are starting new approaches for developing new treatments for cancer-like diseases. Moreover, an increase in funding from pharmaceutical and biotech companies, non-profit organizations, and CROs for oncology clinical trials is further supporting market growth and the development of advanced products to gain substantial market share." #5ForcesofHCT #Pharma #Cancer #ClinicalTrials #Biotech #Biopharma https://lnkd.in/gTEyCcUz

𝗦𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀 𝗿𝗲𝗾𝘂𝗶𝗿𝗲 𝗲𝘅𝘁𝗲𝗻𝘀𝗶𝘃𝗲 𝗿𝗲𝘀𝗼𝘂𝗿𝗰𝗲𝘀 Ongoing research and advancements in CAR-T-cell technology currently unlock new possibilities for personalized and targeted cancer treatments. This groundbreaking approach has demonstrated remarkable success.   The development of such innovative gene & cell therapies raises new hopes for capable treatments against cancer and other diseases.    With this, the demand for high quality plasmid and minicircle DNA increased enormously during the past years, and will, most likely, in the future.   PlasmidFactory prepared itself to be capable of producing High Quality (HQ) DNA in large scale by steadily expanding our production capacities. We are at hand when you need starting material for the GMP production of your CAR-T-cells!   Why choose PlasmidFactory? ✅ guaranteed quantity ✅ Solid experience in the production of CAR plasmids and minicircle ✅ PlasmidFactory’s minicircle significantly improves production efficiency as well as the safety profile of the modified T-cells. Contact us for more information or quotation – we are happy to consult! à info@plasmidfactory.com   PS: Our GMP plant is growing fast: Shortly our manufacturing products are available in GMP grade as well. Join our candidate list to be the first in the line and receive regular update on the progress of our GMP expansion! #CARTcell #GeneAndCellTherapy #Minicircle #GMP #PlasmidFactory

FISH: The Gold Standard for HER2 Testing Our HER2 Gene Amplification Kit (FISH) provides highly accurate DNA-level assessments of HER2 status, guiding doctors in making precise therapy decisions. Key Benefits: 1. Targeted Treatment: HER2-positive patients can choose effective therapies like Herceptin®. 2. Prognosis Insight: HER2 gene amplification indicates a more challenging prognosis. 3. Endocrine Therapy Guidance: Less sensitivity to endocrine therapy in HER2-amplified patients. 4. Chemotherapy Decisions: Guides optimal chemotherapy drug selection. Detect HER2 gene amplification in breast cancer tissue with confidence. #HER2Testing #FISHKit #PrecisionMedicine #CancerDiagnostics #BreastCancerAwareness #GeneticTesting #Oncology #MedicalInnovation #Healthcare #CancerResearch #PersonalizedMedicine #Biotechnology #HealthcareSolutions #ClinicalDiagnostics

Discover the latest insights in Allucent's Monthly Newsletter for the biotech industry: https://lnkd.in/gaWYsp9C This month's Industry Spotlight features: • ADCs, Bispecifics, and Radiopharma leading discussions at ESMO24 • Key FDA approval dates to keep an eye on before year-end • Strategies for advancing precision oncology with radionuclide conjugates and ADCs • A new gene therapy startup gets the green light for a groundbreaking trial • FDA's draft guidance on multiregional clinical trials in oncology • The top contenders in biotech's competitive market

Check out the latest issue of Allucent's Monthly Newsletter for biotech industry highlights: https://lnkd.in/gaWYsp9C   Key Highlights in this month's Industry Spotlight: • ADCs, Bispecifics and Radiopharma Take Center Stage at ESMO24 • 3 FDA Approval Dates to Watch in the Year's Final Push • Advancing Precision Oncology: Radionuclide Conjugate and ADC Development Strategies • Gene Therapy Startup Emerges with Green Light for First-of-its-kind Trial • FDA Issues Draft Guidance on Conducting Multiregional Clinical Trials in Oncology • Who's Winning in Biotech's Tight Market?   #Allucent #BringNewTherapiesToLight #ClinicalDevelopment  #Newsletter

🔬 Dive into the forefront of innovation! 🌟 The abstract submission theme at #ISoP2024Montreal includes "Advanced Therapies" such as Oncology-targeted therapies, Immunotherapy, Gene, and Cell Therapies. Share your expertise and discoveries in these cutting-edge fields. Together, let's advance the future of pharmacovigilance! 🚀🧬 Submit your abstract today: https://lnkd.in/eqPv87CA #AdvancedTherapies #PharmacovigilanceInnovation